OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
KARE59

Karex Bhd

Personal ProductsVerified

Karex Bhd maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.29, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.96, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow is negative at -3.72 million MYR, which may limit its ability to fund operations or growth initiatives without external financing. Profitability metrics for Karex Bhd show a return on equity (ROE) of 1.25% and a return on assets (ROA) of 0.86%, both of which are below the typical thresholds for high-performing companies in the personal care products industry. These figures suggest that the company is generating relatively modest returns for its shareholders and asset base, which may indicate inefficiencies in capital utilization or pricing power. The company's revenue is primarily concentrated in its domestic market, with limited geographic diversification. While Karex Bhd operates in multiple segments, including condoms and feminine hygiene products, the majority of its revenue is derived from a few key product lines, which could expose the company to market-specific risks. The lack of significant international expansion may also limit its growth potential in the long term. Looking ahead, Karex Bhd's growth trajectory appears to be modest. Analysts have assigned a mean price target of 0.70 MYR, with a median of 0.70 MYR, and a mean recommendation of 2.50, indicating a neutral outlook. The company's capital expenditure of -17.81 million MYR suggests a focus on cost management rather than aggressive expansion. While this may help preserve liquidity, it could also constrain long-term growth if not balanced with strategic investments. The risk assessment for Karex Bhd highlights a medium liquidity risk and a low dilution risk. However, the company's net cash position is negative after subtracting total debt, which could pose challenges in maintaining financial flexibility. The absence of strong buy recommendations from analysts further underscores the cautious sentiment surrounding the company's near-term prospects. Recent events and disclosures have not indicated any major operational or financial disruptions for Karex Bhd. The company's financial statements and analyst reports do not highlight any significant recent developments that would suggest a material change in its business model or risk profile. However, the company's reliance on a few core product lines and limited geographic diversification remain key areas to monitor for potential vulnerabilities.

30-day price · KARE+0.00 (+0.0%)
Low$0.49High$0.64Close$0.51As of14 May, 00:00 UTC
Profile
CompanyKarex Bhd
TickerKARE.KL
SectorConsumer Non-Cyclicals
BusinessPersonal & Household Products & Services
Industry groupPersonal & Household Products & Services
IndustryPersonal Products
AI analysis

Business. Karex Bhd is a Malaysian personal care products company that designs, produces, and distributes a range of personal hygiene and wellness products, including condoms, feminine hygiene products, and other related items.

Classification. Karex Bhd is classified under the Consumer Non-Cyclicals economic sector, Personal & Household Products & Services business sector, and Personal Products industry, with a classification confidence of 0.92.

Karex Bhd maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.29, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.96, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow is negative at -3.72 million MYR, which may limit its ability to fund operations or growth initiatives without external financing. Profitability metrics for Karex Bhd show a return on equity (ROE) of 1.25% and a return on assets (ROA) of 0.86%, both of which are below the typical thresholds for high-performing companies in the personal care products industry. These figures suggest that the company is generating relatively modest returns for its shareholders and asset base, which may indicate inefficiencies in capital utilization or pricing power. The company's revenue is primarily concentrated in its domestic market, with limited geographic diversification. While Karex Bhd operates in multiple segments, including condoms and feminine hygiene products, the majority of its revenue is derived from a few key product lines, which could expose the company to market-specific risks. The lack of significant international expansion may also limit its growth potential in the long term. Looking ahead, Karex Bhd's growth trajectory appears to be modest. Analysts have assigned a mean price target of 0.70 MYR, with a median of 0.70 MYR, and a mean recommendation of 2.50, indicating a neutral outlook. The company's capital expenditure of -17.81 million MYR suggests a focus on cost management rather than aggressive expansion. While this may help preserve liquidity, it could also constrain long-term growth if not balanced with strategic investments. The risk assessment for Karex Bhd highlights a medium liquidity risk and a low dilution risk. However, the company's net cash position is negative after subtracting total debt, which could pose challenges in maintaining financial flexibility. The absence of strong buy recommendations from analysts further underscores the cautious sentiment surrounding the company's near-term prospects. Recent events and disclosures have not indicated any major operational or financial disruptions for Karex Bhd. The company's financial statements and analyst reports do not highlight any significant recent developments that would suggest a material change in its business model or risk profile. However, the company's reliance on a few core product lines and limited geographic diversification remain key areas to monitor for potential vulnerabilities.
Key takeaways
  • Karex Bhd has a conservative capital structure with a debt-to-equity ratio of 0.29, but its free cash flow is negative, which may limit its ability to fund growth.
  • The company's ROE and ROA are below industry benchmarks, indicating modest returns for shareholders and asset base.
  • Revenue is concentrated in a few key product lines and the domestic market, which could expose the company to market-specific risks.
  • Analysts have a neutral outlook, with a mean price target of 0.70 MYR and a mean recommendation of 2.50.
  • The company's liquidity risk is medium, and its net cash position is negative after subtracting total debt.
  • Karex Bhd has not disclosed any major recent events that would suggest a material change in its business model or risk profile.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyMYR
Revenue$127.0M
Gross profit$42.8M
Operating income$10.7M
Net income$6.0M
R&D
SG&A
D&A
SBC
Operating cash flow$60.7M
CapEx-$17.8M
Free cash flow-$3.7M
Total assets$703.5M
Total liabilities$220.4M
Total equity$483.1M
Cash & equivalents$43.6M
Long-term debt$140.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$419.8M$1.9M-$1.0M-$38.2M
FY-3$421.6M-$2.9M-$6.2M-$18.3M
FY-2$532.1M$22.4M$10.5M$18.6M
FY-1$507.8M$39.5M$23.4M$12.4M
FY0$498.4M$7.9M$208.0k-$25.8M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$674.8M$465.8M
FY-3$690.6M$457.8M
FY-2$721.7M$476.6M
FY-1$708.8M$482.9M
FY0$763.8M$465.6M
PeriodOCFCapExFCFSBC
FY-4$16.2M-$56.4M-$38.2M
FY-3$554.0k-$35.6M-$18.3M
FY-2$7.0M-$18.7M$18.6M
FY-1$71.1M-$20.7M$12.4M
FY0$28.6M-$43.6M-$25.8M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$127.0M$10.7M$6.0M-$3.7M
FQ-6$123.9M$7.1M$4.8M$1.8M
FQ-5$135.0M$6.4M$1.4M-$3.7M
FQ-4$107.0M$4.0M$3.2M$1.2M
FQ-3$135.7M$8.4M$5.1M-$4.4M
FQ-2$120.8M-$10.9M-$9.5M-$19.5M
FQ-1$133.0M$6.9M$4.6M-$423.0k
FQ0$122.7M-$3.2M-$1.7M-$10.6M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$703.5M$483.1M$43.6M
FQ-6$708.8M$482.9M$39.0M
FQ-5$697.1M$469.9M$45.1M
FQ-4$710.8M$480.0M$45.9M
FQ-3$734.9M$484.6M$28.6M
FQ-2$763.8M$465.6M$33.2M
FQ-1$782.3M$465.6M$24.4M
FQ0$791.9M$454.7M$45.6M
PeriodOCFCapExFCFSBC
FQ-7$60.7M-$17.8M-$3.7M
FQ-6$71.1M-$20.7M$1.8M
FQ-5$18.6M-$5.5M-$3.7M
FQ-4$25.1M-$13.3M$1.2M
FQ-3$13.2M-$28.5M-$4.4M
FQ-2$28.6M-$43.6M-$19.5M
FQ-1-$2.4M-$7.1M-$423.0k
FQ0$25.2M-$18.1M-$10.6M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$483.1M
Net cash-$96.9M
Current ratio2.0
Debt/Equity0.3
ROA0.9%
ROE1.2%
Cash conversion10.1%
CapEx/Revenue-14.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Personal Products · cohort 185 companies
MetricKAREActivity
Op margin8.4%6.0% medp25 0.5% · p75 12.6%above median
Net margin4.7%5.2% medp25 0.5% · p75 10.9%below median
Gross margin33.7%43.2% medp25 26.0% · p75 61.0%below median
R&D / revenue1.8% medp25 1.8% · p75 1.8%
CapEx / revenue-14.0%-3.0% medp25 -5.5% · p75 -1.3%bottom quartile
Debt / equity29.0%13.3% medp25 2.5% · p75 55.2%above median
Observations
IR observations
Mean price target0.70 MYR
Median price target0.70 MYR
High price target0.85 MYR
Low price target0.58 MYR
Mean recommendation2.50 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count2.00
Hold count2.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.01 MYR
Last actual EPS0.00 MYR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-14 00:33 UTC#caa81a2f
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 07:21 UTCJob: 94ca42eb